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There is abundant evidence to suggest that medical cannabis is a valuable resource 
both socially and medically. This thesis presents material which suggests that it is 
advisable for Australia to legalise the use of medical cannabis. 
Research Problem: 
This thesis raises concern surrounding Australia’s current policy on medical 
cannabis. Despite adequate material presenting medical cannabis to be an effective 
medicine in certain cases, and the fact that many developed countries have already 
adopted its use, medical cannabis is currently illegal in Australia.  
Research Method: 
The entirety of this research has been based on a vast array of internationally 
sourced journals, books, internet and newspaper articles. All presented research is 
an analysis of pre-existing texts, experiments and social declarations. Researched 
material within this thesis ranges from advanced medical journals to online 
newspaper articles – a broad scope and academic level of sources was purposely 
selected to avoid bias, opinions and contradictions. 
Results: 
This thesis has established that if implemented correctly, medical cannabis can be 
both a catalyst to a highly equitable industry and also a useful medicinal substance. 
Medical cannabis has also been discovered to be able to positively influence 
numerous social, legal and criminal inadequacies. 
Conclusions: 
It is apparent that Australia could ultimately benefit in numerous political, social, 
legal and economic circumstances if medical cannabis were to be legalised. 
Therefore, Australian policy in regards to the use of medical cannabis needs to be 
reconsidered. 
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Chapter 1: The Introduction 
Chapter 1 Introduction 
This chapter of the thesis will introduce the reader to medical cannabis. Definitions 
of cannabis will be given in this chapter, as will the historical and current medical 
use of the substance. This chapter will provide insight into the overall hypothesis of 
this thesis which debates that there is abundant evidence to suggest that medical 
cannabis is an extremely valuable resource both socially and medically. 
Discussion 
This thesis presents accumulated material, which suggests that the implementation 
of medical cannabis in Australia would be beneficial for the country. The term 
medical cannabis was coined by Dr. Grinspoon and refers to cannabis used for 
medical, not recreational, purpose (Aggarwal, et al. 2012, 1).  This thesis has 
discovered that medical cannabis can present medicinal, social, political and 
economic benefits if correctly implemented. Due to the current position in 
Australian law, cannabis sales are illegal, therefore medical cannabis is illegal in 
Australia (National Cannabis Prevention and Information Center 2013, 3). This thesis 
challenges the negative connotations attached to medical cannabis use by 
presenting material that positions medical cannabis as being a substance that is 
medically useful, safe and economically advantageous. Due to cannabis’ illegal 
position in Australia, this thesis largely analyses writings and experiments produced 
within countries that have already implemented medical cannabis. 
This thesis suggests that cannabis has been presented to hold medicinal benefits, 
most notably its analgesic (pain killing) effect. Cannabis is presented as a fast 
working drug, which can often show medicinal effect within 48 hours (DePetrocellis, 
et al. 1998, 8376). This thesis argues that in comparison to certain harmful 
pharmaceutical drugs, the low chance of overdosing from cannabis suggests that 
there is legitimacy in using cannabis medically. On the lines of cannabis’ medical 
efficiency, this thesis presents the fact that individual cannabis strains are being 
engineered to address separate medical conditions (Mullaway Medical Cannabis Pty 
Ltd 2012, 14). 
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This thesis highlights several methods to consume cannabis other than smoking. 
Removing the action of smoking cannabis can often ease the taboo of cannabis use. 
The thesis presents other advantages in regards to implementing medical cannabis, 
such as how cannabis use can often replace the use of existing medications, alcohol, 
tobacco or illegal drug use (Thomas and Reiman 2013, 7). This thesis also presents 
material that lists numerous medical conditions that cannabis can suggestibly aid, 
such as: cancer, HIV/AIDS, nausea, ‘MS’, epilepsy, strokes, arthritis, diabetes, 
Hepatitis-c, ‘PTSD’, psychosis, depression, schizophrenia, spasms, 
neurodegeneration, heart attack, glaucoma, ‘IBS’, sleeping problems and lack of 
appetite (Pilcher 2005, 214). 
Aside from the presented medical efficiency of cannabis use, medical cannabis is 
presented within this thesis to hold political, social and economic advantages. 
Australia is sited within this thesis to have the perfect climate for outdoor 
cultivation of natural cannabis (Jiggens 2004, 3).  
 
Australia also has a pre-existing Poppy industry that has been presented as being 
capable of producing industrial quantities of medical cannabis (ABC News 2014, 
State Health Minister to discuss medical cannabis trials at the University of 
Tasmanias, par.4). Finally this thesis suggests that medical cannabis can lead to 
many economic advantages if legalised. 
 
The implementation of medical cannabis is presented within this thesis as being 
capable of saving the Australian government considerable amounts of capital 
through reduced prosecutorial, judicial, correctional and police spending (Evans 
2013, 2). The thesis also presents the fact that implementing medical cannabis can 
often lead to a reduction in certain crimes as well as a reduction in the overall 
availability of illegal cannabis (Morris, et al. 2014, 1). By legalising medical cannabis, 
certain users are no longer be forced into contact with illegal drug dealers or 
arrested for trying to buy cannabis. A legal and medical supply of cannabis would 
also insure that the cannabis being provided to the patients is a safe, affordable and 
effective strain, not an unknown source of cannabis from a black market drug 
dealer. 
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This thesis raises concern in regard to the illegal status of medical cannabis under 
the current Australian Drug policy. As of Early 2014, the Cancer Council Australia has 
calculated that Australia has over one hundred thousand cancer sufferers (Cancer 
Council Australia 2014, par.1). This figure suggests that Australia would have a 
considerably large amount of individuals that could benefit from medical cannabis 
legalisation. Presented within this thesis are numerous theories that have come to 
present the positive medical and social outcomes that would emerge if medical 
cannabis is legalised in Australia. The hypothesis of this thesis is thus that there is 
abundant evidence to suggest that medical cannabis is an extremely valuable 
resource both socially and medically. Therefore this thesis ultimately suggests that 
it is advisable for Australia to consider researching the implementation of legalised 
medical cannabis. 
The remainder of this chapter will give a more detailed description of cannabis and 
the ways cannabis can provide positive medical benefit. Separate forms of cannabis 
will be presented within this chapter, so too are the historical and current uses of 
medical  
cannabis. 
(Hazekamp 2007, 4) 
1.1 What is cannabis? 
The plant pictured in Figure 1 
(Hazekamp 2007, 4)  is cannabis, 
scientifically known as Cannabis sativa L. 
(Linnaeus). It is referred to by numerous 
names worldwide such as skunk, 
marijuana, pot, ganja, grass, chanvre,   
cheeba, chronic, weed, reefer, Mary Jane plus 
many more nicknames (United Nations Office on Drugs and Crime 2009, 7). 
Figure 1 (Hazekamp 2007, 4) shows the physical composition of cannabis bud, leaf 
stem and seeds. 
Figure 1 
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‘Cannabis is divided into several subspecies: cannabis sativa, cannabis indica, 
cannabis ruderalis, cannabis spontanea and cannabis kafiristanca, however there is 
no significant differentiation between the sub-species’ (Srivastava, et al. 2014, 
2284). Cannabis is an annually flowering plant, the male plants are taller yet less 
robust than the female plants which can stand anywhere between 0.2- 6.0 meters 
tall (however on average they stand 1-3 meters tall) (United Nations Office on Drugs 
and Crime 2009, 7). The density of the cannabis plant: “depends on environmental 
and hereditary factors as well as the method of cultivation” (United Nations Office 
on Drugs and Crime 2009, 7). A more thorough description of cannabis follows: 
 
 “Cannabis is the generic term used for the psychoactive substance derived from the 
three species of the Cannabis plant. The main psychoactive component in cannabis 
is delta-9- tetrahydrocannabinol (THC). ‘Psychoactive’ means that it has a relatively 
significant effect on the central nervous system. THC potency varies in different 
cannabis products. Cannabis is generally used in three forms: marijuana, hashish 
and hash oil. Marijuana is the dried flowers and leaves of the plant. It is the least 
potent of all cannabis products and is usually smoked. Hashish is made from the 
resin of the plant which is dried, pressed and smoked. It can also be added to food 
and eaten. Hash oil, the most potent cannabis product, is thick oil obtained from 
hashish. It is also smoked” (Australia. Australian Defence Force 2011, 2). 
 
Cannabis has been presented in material to suggestibly possess over 60 chemicals 
which are suggested to have positive medical effect (Allen 2014, par.1). Recently 
great attention has been directed towards ‘the medical properties of chemicals 
present in cannabis alongside its main consistent chemical THC’ (Deiana 2012, 46). 
In summary, there has been key focus upon the chemical components of cannabis 
within medicine, primarily on the chemical THC. The term medical cannabis was first 
coined by Dr. Grinspoon (Aggarwal, et al. 2012, 1), Grinspoon was also one of the 
first doctors to reportedly acknowledge that for ‘centuries certain cultures have 
used cannabis medically’ (Massi, et al. 2003, 838). Medical cannabis has reportedly 
been used within Chinese culture for thousands of years, it was cited as being used 
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as a treatment ‘for at least ten ailments, including nausea and pain’ (Ware, et al. 
2003, 211).  
1.2 The historical use of cannabis 
The practice of using cannabis for medical purpose has been clearly documented in 
material since “ancient times” (Pilcher 2005, 200), cannabis has featured in the 
“pharmacology of many cultures dating back to ancient times” (Pilcher 2005, 
200).The earliest reference to cannabis was during the Ancient Egyptian era in 2000 
BC, where cannabis was used for the treatment of “sore eyes” (Pilcher 2005, 202). 
Circa 1400 BC, cannabis was documented as a flourishing trade commodity which 
was marketed throughout the Mediterranean as a treatment for the ‘pain of child 
birth’ (Pilcher 2005, 202). There has also been evidence of medical cannabis’ in 100 
BC Indian culture and 200 BC Ancient Greek culture. Ancient Rome’s Emperor Nero 
was said to have “praised the medical properties of cannabis around 70 BC” (Pilcher 
2005, 202). As presented by the material, cannabis has been used medically in 
numerous historical cultures throughout numerous historical eras. 
 
Cannabis’ first notable documentation within Western medicine can be traced back 
to 1788, when it had its first European pharmacopoedial reference (Moffat 2002, 
55). However, cannabis was first promoted for medical use in the West as early as 
1621, when Englishman Robert Burton presented cannabis to be an effective 
treatment for depression in his book The Anatomy of Melancholy (Pilcher 2005, 
203). Cannabis was first officially used in Western culture as a medicine for the 
reduction of pain, it was the British during the 1800’s that first adopted the use of 
medicinal cannabis from Indian culture (Pilcher 2005, 203). Physician William 
Brooke o’Shaugnessy started administering medical cannabis in Britain after he 
spent time in India, by 1809 o’Shaugnessy had already started to treat patients who 
had seizures and tetanus with cannabis (Pilcher 2005, 203).  
By 1842 O’Shaugnessy collaborated with Peter Squire to develop “Squires Extract”, 
a cannabis based drug that was “prescribed for pretty much everything” (Pilcher 
2005, 203).  By the start of the 1900’s pharmaceutical companies such as Parke-
Davis, Eli Lilly and Grimault and Company were selling cannabis for conditions such 
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as asthma and pain relief (Mack, Marijuana as Medicine 2000, 17). The evidence of 
cannabis’ therapeutic and medical capabilities convinced the American 
Pharmacopoeia to introduce the substance to their list of approved medicines in 
1950 (Svrakic, et al. 2012, 91). Medical cannabis had become so widely used that 
even influential people such as Queen Victoria were provided cannabis as a 
medicine, Queen Victoria was administered cannabis by her court physician Dr. 
Reynolds (Pilcher 2005, 203). Cannabis’s early use was so prevalent that from 1842 
to 1890, cannabis stayed in “the top three prescribes medicines in the US” (Pilcher 
2005, 204).  
In fact, it was still possible to visit certain UK pharmacies up to 1971 and pick up a 
medical prescription of cannabis (Pilcher 2005, 210). In summary, there have been 
numerous materials which suggest that cannabis has been used as a medicinal tool 
internationally, for centuries.  
 
Figure 2 
 (Mack, Marijuana as Medicine 2000, 16) 
1.3 Current medical use of cannabis 
 
Medical cannabis is currently so entrenched within certain states of the U.S.A that 
New Mexico adopted the medical use of the substance without a single trial (Greer, 
Grob and Halberstadt 2014, 73). Prior to the New Mexico adoption of medical 
cannabis, it had been stated that “there really is massive proof that the suppression 
of medical cannabis represents the greatest failure of the institutions of a free 
Figure 2 
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society, medicine, journalism, science and our fundamental values” (Torres 2014, 
par. 13). Due to evidence gathered from the U.S.A, it would be logical for Australia 
to at least consider researching the medical value of cannabis. 
Currently medical cannabis is available in numerous developed states such as “the 
Netherlands, Israel, 23 states in the U.S.A, Canada and Spain” (Smith 2013, 56). 
Further material has stated that in Europe, certain Cantons (States) in Switzerland 
namely: Vaud, Neuchatel, Geneva and Fribourg as well as the whole of the Czech 
Republic have also legalised medical cannabis (MedicalMarijuana.org 2013, par. 9 
and 36).  
 
 
Figure 3 (Australia. NSW Parliament 2014, 16) 
Figure 3 (NSW Parliament 2014, 16) highlights the 23 states in the U.S.A which have 
implemented medical cannabis. 
Michael Leo Hawkins, B.A. 31218899SWM617 Research Thesis 2014 Supervisor: Professor S.Makinda 
11 | P a g e  
 
 
Perhaps the prominence of medical cannabis’ use in these mentioned countries is 
the reason a 2014 bill was proposed by the Australian ACT Greens which requested 
the implementation of decriminalised cannabis to approved patients. The bill would 
allow patients with a terminal illness to apply for a certification that would prevent 
them from being prosecuted if found possessing small quantities of cannabis. The 
card would be issued by the Department of Health and based on advice from the 
patient’s doctor (Australia. NSW Parliament 2014, 2).  
This ACT Greens bill is supported by Australian medical professionals such as Dr 
Kaye who stated that measures within this ‘bill’ would mean certain Australians 
would no longer have to make the “terrible choice” of breaking the law to gain 
cannabis. Dr Kaye puts forwards that “it is time for science and compassion to win 
out against prejudice and hysteria” (Australia. NSW Parliament 2014, 2), evidently 
Dr Kaye endorses the use of cannabis as a medical tool. It would seem democratic 
that Australian doctors and patients have the option to enquire about the use of 
medical cannabis. The ACT Greens bill could decriminalise cannabis use for ill 
patients, yet it does not address how these Australians would be provided cannabis 
(Boddy and Mcilroy 2014, par.1). The ACT Green’s bill does not aim to supply 
cannabis to the patients, it just removes the criminal prosecution attached to 
cannabis possession.  
More efforts are needed in Australia to be able to research the potential of medical 
cannabis before any decisions on cannabis supply are pursued.  Medical cannabis is 
a relevant issue within Australia, and the implementation of legalised medical 
cannabis may become a more heavily debated issue in the future. This thesis thus 
believes future efforts, such as the proposed medical cannabis bill from the ACT 
Greens are needed if Australia is to successfully consider implementing medical 
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Chapter 1 Conclusion 
In conclusion, this chapter has presented a description and introduction to medical 
cannabis. The historical and current uses of medical cannabis have also been 
presented. This thesis has raised concern that Australia has failed to adequately 
research medical cannabis. Due to numerous developed countries implementing 
medical cannabis in recent years, and the hypothesis that there is abundant 
evidence to suggest that medical cannabis is an extremely valuable resource both 
socially and medically. It is advisable that Australia at least considers researching 
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Chapter 2: Medical debates for the Australian implementation of medical 
cannabis. 
Chapter 2 Introduction 
Throughout this chapter the medical debates for legalising medical cannabis are 
discussed, the general controversies in regard to the legalisation of medical 
cannabis is also highlighted. Presented in this chapter are alternative methods of 
ingesting cannabis which do not include smoking, the remainder of the chapter 
outlines the medical properties of cannabis by presenting a range of illnesses in 
which cannabis has been reported to aid. 
Discussion 
Advanced studies on cannabis have been presented in Harvard University’s research 
carried out in 2007, the research revealed that cannabis can reduce cancer growth 
in three weeks. The Harvard research revealed a chemical in cannabis, 
tetrahydrocannabinol (THC) has the potential to reduce cancer growth. Within the 
research, a controlled batch of cancerous mice was discovered to be 60% more 
likely of cancer retraction when compared to mice not provided with THC 
(Grotenhermen and Muller-Vahl 2012, 495). Even though this research was not on 
humans, it does reiterate cannabis’ ability to combat cancer growth. 
Furthermore, German research in 2012 revealed that cannabis has the ability to 
treat multiple illnesses. The research presented cannabis to be beneficial in aiding 
illnesses ranging from: Parkinson’s disease, Alzheimer’s disease, Tourette’s 
syndrome, Multiple sclerosis, spasms, eating problems, nausea and chronic pain 
(Pilcher 2005, 214). Only considering cancer patients, over 180,000 individuals 
would be eligible for treatment if Australia implemented the use of medical 
cannabis (Cancer Council Australia 2014, par.1). “Todd Mikuriya MD, one of the 
world’s leading authorities on medical marijuana, cites 222 medical conditions 
reported to be helped by using cannabis” (Pilcher 2005, 214). If Mikuriya is correct, 
and cannabis can aid over 222 illnesses, then the Australian health system can 
seemingly benefit from researching medical cannabis. 
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There are three prominent methods within this thesis that present cannabis as an 
effective medical tool: 1) anecdotal evidence of individuals that use medical 
cannabis, 2) medical journals that support the legitimacy of medical cannabis and, 
3) other academic materials that support medical cannabis’ use. RCT’s or Random 
Controlled tests are a clear way of seeing the benefits of medical cannabis. Certain 
RCT’s have revealed that out of 99 human subjects, 82 were convinced that medical 
cannabis was effective (Wodak and Mather 2014, par.13). 
2.1 General controversies regarding the implementation of medical cannabis 
One of the greatest concerns in regard to the legalisation of medical cannabis is the 
view that cannabis use can often be a ‘gateway to harder drugs’. However vast 
research has challenged this gateway drug consensus when suggesting, that an 
individual’s social environment is generally the key gateway to harder drugs, not 
cannabis use (Klofas and Letteney 2012, 11). Another key concern in regards to 
medical cannabis being legalised is the view that cannabis use can increase the 
likelihood of psychosis; however this idea has not been solidified. Most linkage 
between psychosis and cannabis has been attributed to either long term or 
excessive recreational use of recreational cannabis (Hall and Solowij 1998, 1613).  
Medical cannabis is prescribed by doctors in regulated amounts, to assure the 
patient is only relieving their pain, not abusing the substance. As far as patients 
becoming addicted to cannabis are concerned, this has not been suggested as being 
problematic. Cannabis has been presented as being less addictive than tobacco and 
certain conventional medicines such as morphine or opium (Wodak and Mather 
2014, par.6).  
2.2 Alternative cannabis ingestion methods 
Another key concern regarding cannabis use is how ‘smoking is bad for lungs’ 
(J.Baxter, H.Baker and S.Reece 2013, 6), yet this problem can be avoided. The taboo 
of smoking the substance can be removed by using the cannabis in other forms such 
as vapour or liquid. The cannabis substance can be heated up in a vaporizing 
machine, the THC (the chemical within cannabis suggested to reduce pain) is 
extracted into a vapour form that can be inhaled (Wodak and Mather 2014, par.19). 
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The vaporising method ensures that the patients are not be ingesting any harmful 
chemicals or carcinogens, only the medicinal THC is consumed. Other safe methods 
of consuming cannabis are available such as the Sativex spray; this is an oral spray 
that provides all the therapeutic benefits of cannabis. Sativex is available for use in 
numerous countries worldwide, suggesting that it is a reliable method of cannabis 
consumption (Wodak and Mather 2014, par.20). 
Alternative cannabis products to vaporizers also exist, skin patches, inhalers and 
rectal suppositories are also available (Ware, et al. 2003, 214). Further material has 
provided other forms of cannabis products such as ‘oral tablets, cannabis foods and 
drinking teas’ (Mather, et al. 2013, 760). It is becoming justifiable that several 
taboos and concerns in regards to the legalisation of medical cannabis could be 
eased if more explanation was given to those concerned. This thesis debates that 
the Australian legality of medical cannabis by analysing material that suggests 
cannabis is in fact a useful medical substance. 
 
2.3 Medical properties of cannabis 
Prominent research has highlighted cannabis to have an effective analgesic (pain 
killing) effect on humans (Gowing, et al. 1998, 449). In fact, research has revealed 
cannabis to have ‘effective analgesic effect on humans without significantly 
affecting their mood’ (Lucas 2012, Cannabis as an Adjunct to or Substitute for 
Opiates in Treatment of Chronic Pain, 127). The Cancer Council NSW highlighted in 
their 2012 Position statement that cannabis is an effective “analgesic in patients 
with moderate to severe pain” (Cancer Council NSW 2012, 1). With so many 
variations of pain killers available in Australia, why would the implementation of 
one more be so controversial?  
Two chemicals within cannabis have been presented to be specifically 
advantageous in medicine; they are the chemicals THC and CBD. THC is said to hold 
analgesic, anti-spasmodic, anti-tremor, anti-inflammatory, anti-emetic and appetite 
stimulant properties. Whilst CBD has been cited as containing an: anti-
inflammatory, anti-convulsant, anti-psychotic and anti-oxidant effect on humans 
(Pilcher 2005, 214). 
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Cannabis produces its medicinal effects by binding to receptors in the human body, 
cannabis binds both to the body receptor CB1 which is in the brain, and receptor 
CB2 which is in the immune system (Massi, et al. 2003, 838). It has been put 
forward in the German medical journal Deutsches Arzteblatt International that ‘the 
various medical properties of cannabis lay in their ability to activate the bodies CB1 
and CB2 receptors’ (Grotenhermen and Muller-Vahl 2012, 500). 
Cannabis is a fast acting drug, for example: as far as apoptosis (death) in cancer cells 
is concerned – cancer cells can be significantly damaged within 48 hours 
(DePetrocellis, et al. 1998, 8376), and complete tumour apoptosis can occur in 
72hours (Preet, Ganju and Groopman 2008, 340). Neurodegeneration has also been 
cited as having a fast acting recovery when treated with cannabis. Studies have 
shown neurodegeneration to be prevented by up to 36% within the period of one 
week (Van Der Stelt, et al. 2001, 6475). 
Different strains of cannabis have been suggested to be effective in tackling 
different forms of illnesses; Mullaway Medical Pty Ltd has successfully been 
engineering different strength of medical cannabis products that address numerous 
illnesses (Mullaway Medical Cannabis Pty Ltd 2012, 14).  This medical tailoring of 
cannabis is confirmed when it is presented that ‘medical cannabis is so entrenched 
in Dutch society, that they have engineered different strains of cannabis to deal 
with different diseases’ (Johns 2014, par.9). Such innovations as tailored cannabis 
can assure that no matter the severity of illness, there can be a product designed to 
suit any patient’s needs. The fact that cannabis products can now be tailored to a 
doctor’s requirement, suggests that cannabis is possibly safe enough to be 
implemented within the Australian medicine. 
Unlike some already approved pharmaceutical medications for example opium, 
cannabis is unique in the quality that it has been presented as impossible for 
humans to overdose from it. Thomas and Reiman suggest this when they put 
forward “there is no amount of marijuana than can result in an overdose” (Thomas 
and Reiman 2013, 7). Separate material supports the safety of cannabis: ‘unlike 
other pharmaceutical drugs, cannabis is safer in the way that you cannot overdose 
from it’ (Smith 2013, 57). Dr. Allen reinforces the idea of cannabis ’safety when he 
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states that humans can handle “extremely high doses” (Allen 2014, par.3) of 
cannabis. As far as humans are concerned, it has been suggested that cannabis is 
not overtly harmful. Medical research suggests that 99% of the time the main side 
effect of cannabis use is “dizziness” (Degenhardt and Hall 2008, 1685). In fact it has 
been presented that 71% of patients which used medical cannabis actually saw their 
condition worsen when they discontinued cannabis use (Topp 2006, 12). 
Mainly due to the two substances sharing similar medical qualities (Lucas 2012, 
Cannabis as an Adjunct to or Substitute for Opiates in Treatment of Chronic Pain, 
125), there are numerous materials that suggests cannabis can replace the use of 
opiates in pharmaceuticals. Australian Senator Di Natale reiterates this point when 
she suggests that ‘cannabis is far less addictive than many currently available opiate 
medications’ (Sky News 2014, par.13).  
 ‘The existence of other harmful pharmaceutical medications within the Australian 
medical system’ (Gowing, et al. 1998, 446), may make it possible to replace some of 
these harmful medications with the option of medical cannabis (Thomas and 
Reiman 2013, 7). Previous studies on illegal medical cannabis use in Australia taken 
out by the New South Wales State Government revealed that out of 128 
participants, 62% of them had discontinued use of other medications once they had 
used cannabis as a replacement (Swift, Gates and Dillon 2005, 5).      
Further research carried out in Canada revealed that out of 404 participants, 67.8% 
of them stopped using other prescribed medications once they were provided 
cannabis as a replacement (Lucas, Reiman, et al. 2012, 1). 
Cannabis is also presented to share similar qualities to many anti-psychotic 
medications (Deiana 2012, 46); this again supports the point that cannabis could 
replace some existing medications in Australia. Furthermore, material by Lucas 
presents another positive correlation with legalising medical cannabis; Lucas 
suggests medical cannabis can reduce alcohol and illegal drug use. A certain medical 
cannabis trial presented that 36.1% of the participants had stopped using other 
illegal drugs once prescribed cannabis; a further 41% of the participants were 
presented to have stopped consuming alcohol (Lucas, Reiman, et al. 2012, 1). 
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Figure 5  
 
 
(Swift, Gates and Dillon 2005, 6) 





Figure 4 (J.Janichek and A.Reiman 2012, 3) reinforces how cannabis may lead to a 
decline in tobacco, alcohol and illegal drug use. 
 
Figure 5 (W.Swift, P.Gates and P.Dillon 2005, 6) highlights how 
cannabis may be an efficient replacement to existing 
medications. 
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can aid 
Cannabis has been presented in certain material to be effective at combating 
numerous illnesses; one of the most prominent is cancer. It was put forward in 
research from Harvard University that ‘THC has the ability to inhibit tumour growth’ 
(Preet, Ganju and Groopman 2008, 339). Many chemical components of cannabis 
such as THC and temazolamide (TMZ) have been presented within medical research 
to ‘reduce the growth of cancer cells’ (Torres, Lorente and Rodriguez-Fornes 2011, 
90).  
Certain cannabinoids in cannabis are presented to fight cancer, generally via two 
methods. First it can kill cancer via tumour vascularization (by reducing the capacity 
of blood vessels within the tumours); or secondly it can cause cancer death by 
apoptosis (cancer death by fragmentation or shrinkage) (Caffarel, et al. 2010, 3). 
Research has suggested that THC can successfully reduce ‘the growth, number, 
amount and severity of lung cancers’ (Caffarel, et al. 2010, 1). It was concluded in 
the American Association for Cancer Research report for 2006 that, ‘the apoptosis 
of tumour cells when exposed to cannabinoids, validates the use of cannabis in 
medicine’ (Carracedo, Gironella and Lorente 2006, 6748). 
 
Figure 6   (Gardner 2013, 1) 
 
Figure 6 (Gardner 2013, 1)  shows the almost periodical regression of a brain 
tumour (the white mass in the center of the brain) after 15 months of cannabis 
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Cannabis has been presented to be effective towards fighting breast cancer by 
inhibiting cell growth. The National Academy of Sciences (U.S.A) has presented that 
cannabis is effective at combating the ‘fast acting tumours in breast cancer’ 
(DePetrocellis, et al. 1998, 8375). Cannabis has also been presented as being 
efficient in fighting brain tumours; research published in the British Journal of 
Cancer supported this. The journal revealed that a proportion of terminal patients 
were administered cannabis to aid their cancer treatment, the research revealed 
that patients who used cannabis, saw an increased lifespan of 46-60% when 
compared to patients not provided cannabis (Guzman, et al. 2006, 197). This British 
research has suggested that cannabis can aid sufferers of breast cancer. This 
positive correlation between breast cancer reduction and cannabis cannot be 
solidified within Australia unless there is a change in the current national drug 
policy, which allows medical cannabis research.  
Research published within the US National Library of Medicine has presented how 
prostate cancer can be decreased if exposed to cannabinoids (Mimeault, et al. 2003, 
1-12). Similar study published by the American Journal of Cancer also presented 
cannabis to be effective in combating pancreatic cancer (Carracedo, Gironella and 
Lorente 2006, 6748). The US National Library of Medicine has also published 
material which suggests that cannabis is effective in combating the side effects of 
leukaemia (Jia, et al. 2006, 549). Separate research has similarly presented cannabis 
to be effective in combating multiple cancers such as lung cancer (Preet, Ganju and 
Groopman 2008, 342), liver cancer (Vara, et al. 2011, 1099) and glioblastoma 
(Torres, Lorente and Rodriguez-Fornes 2011, 90). There is clearly material which 
suggests cannabis can be effective in fighting multiple forms of cancer, with 
Australia being a high risk country for cancer, it is considerable that any medication 
that could combat cancer would be embraced within Australia. 
Material has also presented cannabis to be effective in reducing certain side effects 
of HIV/AIDS. By increasing the bodies’ appetite, cannabis is presented to be an 
effective tool in combating the weight loss symptoms that frequently accompany 
the HIV illness (Gowing, et al. 1998, 447). Cannabis is also presented as a key 
suppressant of vomiting; vomiting is often presented as another side effect of 
HIV/AIDS (Smith 2013, 57). The Clinical Science Journal also presents research that 
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suggests cannabis is beneficial for HIV/AIDS sufferers, trials were taken out on 
HIV/AIDS patients that revealed cannabis to be effective in increasing appetite and 
vomit suppression (Haney, et al. 2007, 545). This information suggests that cannabis 
can be an effective medicine for HIV/AIDS sufferers.  
Nausea is a further illness that has been suggested to be suppressed when treated 
with cannabis, the efficiency of cannabis in its relation to suppressing nausea is 
supported when a trial presented that 86% of the participants saw a reduction in 
nausea once they had consumed cannabis (Swift, Gates and Dillon 2005, 5).  
As mentioned, cannabis has been demonstrated in numerous materials to have 
‘positive effect appetite and food intake’ (Smith 2013, 56). Cannabis is said to 
produce hunger in the brains feeding receptors, therefore increasing the food 
intake of cannabis users (Australia. National Cancer Institute 2014, par.11). The 
Cancer Council NSW Factsheet has highlighted cannabis as being particularly 
effective for patients suffering “weight loss and muscle wasting” (Cancer Council 
NSW 2012, 2). Being presented in the Fact Sheet of the Cancer Council NSW, 
medical cannabis is visibly gaining professional attention in Australia. If Doctors 
within the Cancer Council have already advocated for the legalisation of medical 
cannabis, it is clear that medical cannabis has a prominent and informed medical 
backing within Australia.  
Sufferers of Multiple Sclerosis or ‘MS’ have also been presented within material to 
benefit from cannabis use. Cannabis is reportedly able to “alleviate an entire range 
of symptoms associated with MS” (Smith 2013, 57). It has been suggested in the 
1998 American Drug and Alcohol Review that ‘spasms associated with MS may be 
relieved once the patient has used cannabis’ (Gowing, et al. 1998, 447). It has been 
suggested that cannabis is such an efficient medicine for MS that even the placebo 
of using cannabis has been presented in certain cases as being beneficial in MS 
patients (Thomas and Reiman 2013, 5). 
The medicinal properties of cannabis are also presented to be productive in 
combatting the main effects of epilepsy. The effectiveness of cannabis in regards to 
treating epilepsy is notable in the case of an unnamed West Australian youth. The 
youth went from ‘being unable to efficiently walk and talk, to being able to run and  
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string full sentences together, after just one week of cannabis treatment’ (Murray 
2014, 37). Epilepsy and cannabis have had a long historical correlation; in 1878 the 
U.S.A published the first medical journal which confirmed that cannabis is an 
effective tool in reducing epileptic fits (Phillips 2014, par.16 ). In 2003, the British 
Medical Association concurred that cannabis is effective in combating epilepsy; they 
approved a cannabis based drug for use on certain epileptic patients (Phillips 2014, 
par.5 ). It has been cited that certain epileptics in Australia have resorted to 
dangerous and illegal methods to gain cannabis, methods such as associating with 
‘underground drug networks’ (Murray 2014, 37) . It is a concerning fact that 
epileptic patients in Australia disregard their own safety in order to obtain cannabis, 
cannabis that would be available to them legally if they lived in a ‘medical cannabis 
country’ such the Netherlands or Czech Republic. 
Seizures are commonly associated with epilepsy; however they can emerge from 
many numerous medical conditions. Within Australia there have been certain cases 
of cannabis being successful in reducing seizures; one example is the case of Tara 
O’Connell. Tara used to suffer up to 200 seizures a day, since Tara started using oil 
made from cannabis her “seizures have stayed away” (Su 2014, par.7). A second 
example of cannabis aiding epilepsy can be seen in the case of a British infant who 
was “convulsing almost constantly” (Phillips 2014, par.1). The Doctor administered 
the child with cannabis oil and supposedly “stopped the seizures almost 
immediately” (Phillips 2014, par.3). Material has presented there are certain cases 
which have highlighted the positive effect medical cannabis has on reducing 
seizures, therefore seizures are another condition that could be medicated if 
Australia legalised medical cannabis. 
Strokes are another condition which have been reported as treatable when exposed 
to cannabis. THC has been presented in certain cases by the US Department of 
Health and Human Services to protect the brain from strokes, it does this by 
reducing the likelihood of ‘low blood flow to the brain’ (Allen 2014, par.1). If 
research by the US government has revealed a positive relationship between 
cannabis and the reduction of strokes, why has the Australian government not 
considered these findings? 
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Cannabis has also been suggested to be beneficial to sufferers of arthritis; tests 
carried out at London Imperial College showed the inflammation of arthritis 
sufferers can be decreased by up to 50% when cannabinoids were administered 
(Reichard 2012, par.12). With positive British results in regard to cannabis’ effect on 
arthritis, Australian researchers should also have ground to test the efficiency of 
cannabis on arthritis. 
Cannabis has also been presented as being effective in reducing the likelihood of 
diabetes; research has suggested that cannabinoids can reduce the likelihood of 
diabetes by up to 58% (Torres 2014, par.36). One research carried out on 
experimental mice, presented that only 30% of the mice which had been using 
cannabis showed signs of diabetes, compared to a 90-100% rate of diabetes within 
mice that were not provided cannabis (Reichard 2012, par.13). International 
material has revealed a correlation between cannabis use and the reduction of 
diabetes, therefore diabetes is yet another example of an illness that could be 
addressed, if medical cannabis were to be legalised in Australia. 
Hepatitis-c is a further illness that cannabis has been presented to be successful in 
reducing; the Wyoming Institute of Technology conducted supporting research that 
presented results which supported cannabis’ efficiency in combating hepatitis-c. In 
human trials on Hepatitis-c sufferers, 99.8% of the subjects were cured of the 
illness; the remaining 0.2% showed advanced signs of hepatitis-c reversal (Stone 
2013, par.3). This research by a respectable institution enforces the view that 
cannabis has a potential to reduce hepatitis-c. With a presented cure ratio of nearly 
100%, there should be grounds for an Australian study on cannabis’ medical 
potential in relation to hepatitis-c.  
Individuals who suffer from sleeping problems such as insomnia are also presented 
to benefit from cannabis use; this is simply because sleep is often found to increase 
with cannabis use (Ware, et al. 2003, 211). Research published in the International 
Journal of Drug Policy has cited cannabis to be an effective medicine for patients 
who have trouble sleeping (Walsh, et al. 2013, 511). A survey of 127 insomnia 
patients revealed that 86% had seen an improvement in their sleeping pattern once 
they were provided cannabis (Swift, Gates and Dillon 2005, 5). Cannabis could 
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possibly help a range of Australian insomniacs which include shift and FIFO (fly-in 
fly-out) workers with sporadic work schedules. Being a non-fatal illness, insomnia 
can also offer Australian researches a vital chance to study the long term effects of 
cannabis use on humans. 
Post-Traumatic Stress Disorder (PTSD) is yet another illness that cannabis has been 
presented to be effective in addressing. The Journal of Psychoactive Drugs has put 
forward that during a test on 80 participants with PTSD, 75% of the participants had 
showed improvement once they were provided cannabis. The journal came to the 
conclusion that cannabis is directly associated with a reduction in PTSD (Greer, Grob 
and Halberstadt 2014, 73). This evidence is reinforced in the case of US Army 
veteran Matt Kahl who declared ‘cannabis to be the only medication that allows 
him to control his PTSD’, Kahl admitted that he went from being ‘suicidal to stable, 
once he was provided cannabis as a medication’ (Diente 2014, par.5). 
The cannabinoid, cannnabidiol (CBD) has been credited in a publication by the Drug 
Testing and Analysis Journal as being highly effective towards reducing psychosis. 
The journal states that CBD has non-psychoactive properties that help the brain 
reduce the likelihood of psychosis (Deiana 2012, 46). With mental health being an 
ongoing issue within Australia, it may be beneficial for the country to invest in 
studies which analyse the relationship between cannabis and psychosis. 
Still on the topic of mental health, cannabis has also been presented to have a 
positive effect on sufferers of depression. Denson and Earleywine put forward in 
their article Addictive Behaviours, those cannabis users often “had less depressed 
mood, more positive effect, and fewer somatic complaints than non-users” (Denson 
and Earleywine 2005, 1). The same article researched the benefits of recreational 
cannabis use compared to medical cannabis use, it was discovered that recreational 
smokers tended to be less depressed than medical users. This research suggested 
that it was most likely the individual’s illness, not the cannabis use that was catalyst 
to their depression. One of the key concerns in regards to medical cannabis being 
legalised is the view that cannabis can increase the likelihood of psychosis; however 
this article has suggested this opinion to be generally incorrect.  
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Conventional anti-psychotic medication has been noted to frequently have little 
effect on schizophrenic patients, for this reason cannabis has been suggested to be 
an appropriate alternative to generic schizophrenia medications (Deiana 2012, 46). 
Further research from Canada has again suggested that cannabis does not have a 
negative effect on schizophrenic patients (Morris 2014, par.1). This suggests it may 
be possible for the Australia to consider treating schizophrenic patients with 
cannabis, if their conventional medication is not working. 
Certain material has presented cannabis to be effective in reducing the negative 
side effects of spinal cord injury. The spasticity, spasms and pain that prominently 
accompany spinal cord injury are suggested to be relieved if cannabis is used 
(Gowing, et al. 1998, 447). With Australia being a keen participant of contact sport 
such as rugby and AFL, there is a high probability that spinal damage will be an 
ongoing problem within Australian society. Therefore medical cannabis should be 
researched within Australian sport science. 
Research has presented cannabis to be effective in reducing neuronal damage also 
known as neuro degeneration; in 2001 the Dutch Journal of Neuroscience published 
results that supported these findings. The journal suggested that THC was 
successful in reducing neuronal damage by up to 36% within only 7 days (Van Der 
Stelt, et al. 2001, 6475). The neuropathic properties of cannabis have also been 
presented within the Australian Drug and Alcohol Review of 1998 when it was 
suggested that cannabis ‘has the ability to reduce neuro pain' (Gowing, et al. 1998, 
451). Having been cited in the Australian Drug and Alcohol Review as holding 
therapeutic value almost 17 years ago, it is surprising that Australia still lacks 
professional research regarding medical cannabis’ medical potential. 
Further material has suggested cannabis could benefit certain individuals prone to 
heart attack by reducing blood flow, cannabinoids are suggested to reduce the 
probability of heart attacks by up to 66% (Torres 2014, par.21). Heart attacks are 
genetic, so theoretically cannabis could be used as a preventative medicine to 
reduce the likelihood of heart attack. Unless Australia changes its cannabis policy, 
preventative cannabis use for heart attack prone individuals will stay theoretical. 
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It has been put forward in the Journal of Gastroenterology and Hepatology that 
cannabis ‘is effective in reducing inflammatory bowel disease (IBS)’. The journal 
states that in a human study, 5 out of 11 IBS sufferers experienced complete 
remission, and 10 out of 11 saw improvement once provided with THC (Naftali, et 
al. 2013, 1276). Having personally witnessed a series of IBS adverts on Australian 
Free to air television, it is clear that the illness is not an irrelevant issue in Australia. 
If Australia legalised medical cannabis, cannabis could be used as a natural 
alternative to current IBS medications. 
The vision impairment Glaucoma is the final condition presented within this thesis 
to be respondent to cannabis treatment; by reducing the blood flow to the eye, 
cannabis has been shown to be effective in clearing the ‘blurry’ vision of glaucoma 
sufferers (Gowing, et al. 1998, 448).  
 
Figure 7 (Colorado Department of Health and Environment 2014) 
 
Figure 7 (Colorado 
Department of Health 
and Environment 2014) 
highlights the symptoms 
that Colorado, U.S.A 
medicates with cannabis. 
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                (Swift, Gates and Dillon 2005, 5)  
 
 
The ‘discontinue’ rate of medical cannabis supports its reputation as a useful 
medicinal product, only 10% of medical cannabis users surveyed in the U.S.A have 
discontinued use (Mather, et al. 2013, 760). The fact that only a small percentage of 
medical cannabis users decide to discontinue use, suggests that users of cannabis 
are reporting a medical improvement. The American Medical Association supports 
that cannabis is a legitimate medicine; in 2009 the association added the substance 
to their list of approved prescription drugs (Mather, et al. 2013, 759). This raises the 
debate, why to date has Australia ignored the medicinal properties of cannabis 
presented by the U.S.A?  
Figure 8 (W.Swift, 
P.Gates and P.Dillon 
2005, 5) outlines 
numerous amounts 
of illnesses that have 
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Chapter 2 Conclusion 
It has been suggested through an array of material in this chapter, that cannabis can 
be used to address numerous illnesses in Australia. Ranging from cancer to MS, this 
chapter has presented multiple conditions that have been treated internationally 
with cannabis. This chapter has presented the general controversies in regard to 
cannabis use, followed by numerous ingestion methods that are available for 
cannabis. This thesis suggests that Australia would benefit from researching the 
medicinal effects of cannabis, throughout new research the Australian government 
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Chapter 3: Political and Socio-Economic debates for the Australian 
implementation of medical cannabis. 
Chapter 3 Introduction 
Throughout the duration of this chapter, the current legal status of medical 
cannabis in Australia is discussed. Presented within this chapter of the thesis are the 
economic and social advantages that can accompany legalising medical cannabis. 
The political, social and organisational acceptance of medical cannabis within 
Australia and internationally are also discussed. 
This chapter will start by presenting the current legal status of cannabis in Australia. 
The social, organisational and political acceptance of cannabis in Australia is then 
discussed. The chapter concludes by presenting the social and economic advantages 
that have been presented to accompany the implementation of medical cannabis. 
Discussion 
3.1 The current legal status of cannabis in Australia  
Currently Australia does not legally allow the use of cannabis in its Therapeutic 
Goods Administration (Baxter, Baker and Reece 2013, 1). Cannabis was originally 
banned in 1925 following the result of a League of Nations summit; Victoria was the 
first state to outlaw cannabis in 1928. However the League of Nations ban did not 
take full effect in Australia for another three decades (Mather, et al. 2013, 759). On 
the back of limited research, cannabis was categorised as harmful as cocaine, heroin 
and morphine then therefore made illegal (Fitzgerald 2013, par.16). Following the 
League of Nations ban, cannabis was categorised as illegal in Australia and 
internationally. 89 years after the 1925 League of Nations summit on cannabis, 
countless numbers of individuals have been jailed due to cannabis use and millions 
in government capital has been spent on enforcing the cannabis ban.  
Australia is signatory to numerous international agreements that restrict the use of 
cannabis in any form (Australia. NSW Parliament 2014, 8). For instance, Australia is 
signatory to the 1961 United Nations Single Convention on Narcotic Drugs, this bans 
the use of medical cannabis (Australia. NSW Parliament 2014, 8). The 1988 UN 
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Convention against Illicit Traffic in Narcotic Dangerous Psychotropic Substances also 
restricts Australia from being able to import cannabis (Australia. NSW Parliament 
2014, 8). There are also numerous Commonwealth laws that restrict the use or 
importation of cannabis in Australia. Such laws as the 1995 Criminal code Act, 1901 
customs Act, 1956 Customs (Prohibited Imports) Regulations, 1967 Narcotic Drugs 
Act, 1989 Therapeutic goods Act and the 1990 (Traffic in Narcotic Drugs and 
Psychotropic Substances) Act all ban the use of cannabis (Australia. NSW Parliament 
2014, 8-9). Clearly Australia is signatory to numerous agreements that restrict the 
use or importations of cannabis within the country, these mentioned laws are the 
key reason that medical cannabis is illegal in Australia. 
 ‘As mentioned, there are ‘international legal obligations’ that currently prohibit 
Australia from using medical cannabis, these obligations mean that citizens found in 
possession of small amounts of cannabis can receive large fines (Topp 2006, 13).  
Australia is signatory to further international treaties which makes it illegal to sell, 
use or produce any cannabis product such as the 1995 Commonwealth Criminal 
Code section 307.5-307.7 which outlines how it is illegal to import or export any 
form of cannabis, and section 307.1-307.4 that highlights how it is also illegal to 
possess any form of cannabis (Australia. NSW Parliament 2014, 22). According to 
current Australian law, cannabis is a class 9 illicit drug, which puts it in the same 
category as heroin and LSD (acid) (Smith 2013, 56).  
Drug laws within Australia are primarily enforced on the state level, however in 
Australia cannabis comes under a full national restriction (Smith 2013, 56). In the 
Australia Capital Territory (ACT), South Australia (SA) and the Northern Territory 
(NT) cannabis has been decriminalised, this means although still illegal, the 
repercussions for having cannabis are smaller in these states. In the ACT if someone 
is caught with up to two cannabis plants or 25 grams of dried cannabis they can 
receive a $100 fine, In SA individuals with100 grams of cannabis or one plant can 
receive a $50-$150 fine and in the NT 50 grams of cannabis or two plants could 
bring an individual a $200 fine (National Cannabis Prevention and Information 
Center 2013, 1).  
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Figure 9 (National Cannabis Prevention and Information Center 2013, 2) 
In contrast to the ACT, SA and the NT, cannabis is completely illegal in the remaining 
states of Australia. This means individuals found in possession of cannabis can 
endure much more detrimental penalties than those in the decriminalised states of 
ACT, SA and NT.  In New South Wales, cannabis possession of 15 grams is given two 
cautions before criminal charges may be placed. Victoria allows up to 50 grams of 
cannabis but only offers two cautions before charges are placed. Tasmania offers 
three cautions of up to 50 grams, while Queensland only offers one caution of 50 
grams. Western Australia could be seen to have the strictest penalties, any 
individual found with 10 grams of cannabis are automatically made to face a 
criminal charge, fine or “cannabis intervention session” (National Cannabis 
Prevention and Information Center 2013, 3). The cannabis intervention session is a 
rehabilitation program that aims to assist offenders in quitting cannabis use. 
Figure 9 (National Cannabis Prevention and Information Center 2013, 2) 
outlines the differing cannabis laws within the three Australian states that 
have decriminalised cannabis. 
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(National Cannabis Prevention and Information Center 2013, 4) 
 
3.2 Political, Social and Organisational Acceptance of Cannabis 
Cannabis has been reported as being the world’s most frequently consumed illicit 
drug (Hall 2000, The cannabis policy debate: finding a way forward, 1690). That 
statistic does not differ in Australia, the Cancer Council New South Wales has 
reported cannabis as being the most commonly used illicit drug within the country 
(Cancer Council NSW 2012, 1). In 2010, the Cancer Council reported that 1.9 million 
adults within Australia have tried cannabis (Cancer Council NSW 2012, 1). Research 
has calculated that 40% of the country has tried cannabis, including 300,000 
Australians that use cannabis daily (Smith 2013, 56). The consumption of cannabis 
within Australia is much higher than the average country, Australia and their 
geographical neighbours New Zealand are cited as being the countries with the 
most prevalent cannabis use (Baxter, Baker and Reece 2013, 1). In summary, certain 
Figure 10 (National Cannabis Prevention and Information Center 2013, 4) 
highlights the methods put in place by Australian states that consider cannabis 
illegal. Note that unlike the ‘decriminalised’ cannabis states in Australia, you 
cannot simply pay a fine if you are found in possession of the substance. 
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material has presented a significant percentage of the Australian population to find 
cannabis an accepted and frequently used substance.   
Illicit substances such as opium are frequently used as ingredients in modern 
medical products. This concern was raised in Australia when Premier Campbell 
Newman questioned ‘why is opium currently used in medical practice yet cannabis 
is not’ (Vogler 2014, par.4)? This concern is again expressed when it is quoted by 
Murray that “We grow opium poppies in Australia in secure locations for their 
accepted use in our most effective painkillers…[S]urely we can do the same with 
marijuana” (Murray 2014, 37).  
Cannabis has been presented to hold similar painkilling attributes as opium. 
Cannabis being a less addictive substance than opium would mean that the 
implementation of cannabis in opium’s place could reduce the likelihood of opium 
dependence or withdrawal symptoms becoming problematic for patients 
(McGowan 2014, 70). It appears possible to consider the use of cannabis in 
circumstances where opium addiction has been problematic. The use of cannabis in 
place of opium seems possible due to the similarities between cannabis and opium, 
the possibility that cannabis might be less addictive than opium can also be seen as 
being advantageous.  
Former NSW Premier Bob Carr is a passionate campaigner for medical cannabis 
implementation in Australia (Hansen 2014, par.12). In 2003, the Carr government 
announced its intention to introduce a four year medical cannabis trial; however 
cannabis supply issues prevented the trial from ever taking place (Australia. NSW 
Parliament 2014, 5). Australia had another chance to change their law on medical 
cannabis in 2013 when a New South Wales Parliament Committee put forward an 
amendment to facilitate terminally ill patients the right to possess up to 15grams of 
cannabis for medical purposes (Coultan 2013, par.1). However, this proposal was 
denied by the New South Wales Government, it was denied due to a ‘lack of 
evidence supporting cannabis, and its relation to pain relief’ (Hawke 2013, par.13). 
Australian politician MP Kaye was quoted as being ‘disappointed’ with the 
conclusion to the 2013 New South Wales amendment, similarly former Australian 
MP O’Grady was also said to be correspondingly dejected. O’Grady suggested that 
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‘good policy is evidence based’ and a medical cannabis trial needed to have been 
performed before the amendment was denied (Hawke 2013, par.9). This thesis 
believes processes such as the bills from the O’Grady and Carr governments’ are the 
most ethical way of approaching legalised medical cannabis. In order for medical 
cannabis to be implemented there must first be ethical bills presented to the 
Australian government that entail professional research and analysis on medical 
cannabis. 
Political support of medical cannabis’ implementation in Australia is again visible in 
the forms of medical cannabis bills being drafted by John Kaye of the NSW Greens 
party; this bill will see certified patients legally allowed to possess small amounts of 
cannabis for medical use. Similarly the NSW Nationals MP Kevin Anderson is also 
drafting a separate medical cannabis bill; Anderson is quoted to ‘not condone the 
use of drugs’ (Hansen 2014, par.16) however after researching cannabis’ positive 
benefits,  Anderson decided to pursue the medical cannabis bill (Australia. NSW 
Parliament 2014, 2). Both Kaye and Anderson’s bills are expected to be released by 
the end of 2014, so too is a separate Western Australian medical cannabis bill 
(Washer and Langman 2014, par.4-5).  
Green’s Senator Di Natale reinforces her wish to see Australia legalise medical 
cannabis when she states that ‘it is cruel to deny patient’s medical cannabis, since 
research has presented its legitimacy’. The same material reiterates this point when 
it is stated that Liberal co-convenor Stone suggests that ‘Australia join other 
developed states with the implementation of medical cannabis’ (Sky News 2014, 
par.8). This acceptance of medical cannabis at a political level in Australia 
thoroughly enforces the relevance and legitimacy of this overall thesis. 
The debate regarding medical cannabis’ implementation in Australia is often 
prominent in political material. Medical cannabis has been thoroughly promoted by 
numerous Federal and State politicians in Australia such as: NSW Premier Mike 
Baird, WA Labor Leader Mark McGowan, MP Mal Washer and MP Melissa Parke 
(McGowan 2014, 70). Mark McGowan, leader of the Western Australian (WA) Labor 
Party has supported medical cannabis since 2010. McGowan had a friend that 
passed away at thirty years of age, Prior to his passing, McGowan’s’ friend’s only 
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highlight to the day was apparently “when he smoked cannabis in a quiet courtyard 
to ease his pain” (McGowan 2014, 70). Ever since McGowan’s friend passed away, 
the leader of the WA Labor Party has advocated for the use of medical cannabis. 
 With the Leader of the WA Labour Party advocating the use of medical cannabis, it 
only seems logical that Australia pursues the issue more thoroughly. McGowan 
adequately summons his view the following quotation: “We need laws to support 
people with chronic or terminal illnesses who find cannabis relieves their symptoms 
and pain” (McGowan 2014, 70). A final bill presented by Australian Capital Territory 
(ACT) MP Rattenbury presented that an overwhelming 70% of Australians support 
the use of medical cannabis (Rattenbury 2014, 1). Visible in the forms of the 
multiple medical cannabis bills presented in Australia as well as the advocacy from 
multiple politicians, it is clear that there is a large amount of political support for 
medical cannabis in Australia. 
There is a vast amount of organisational support for medical cannabis presented 
from the U.S.A, this is visible in the form of surveys taken out on medical doctors 
(MD) and police officers in the U.S.A. Revealed within the survey is that, 69% of 
MD’s believe that cannabis should be available for medical use (Medical Cannabis 
Australia 2014, New Poll: 69% of Physicians in the U.S. Believe Cannabis Has 
Legitimate Medical Benefits, par.1). A second survey taken out on 11,000 police 
officers revealed that 65% of them not only believed cannabis should be available 
for medical use, but also believed cannabis should be decriminalised or legalised 
throughout the U.S.A (Medical Cannabis Australia 2014, New survey: 64% of Law 
Enforcement Officers Want Cannabis Laws Reformed, par.1). It seems logical to at 
least research medical cannabis within Australia due to the 69% of MD’s and 65% of 
police officers in the U.S.A that promote the legalisation of medical cannabis. These 
surveys are not the opinions of biased individuals; they are the opinions of qualified 
doctors and law enforcement officers. Former US President Bill Clinton clarifies that 
the U.S.A implemented medical cannabis due to “a lot of evidence that it helped 
patients” (Edwards 2014, par.3), why has the Australian government not analysed 
this “evidence” of cannabis being medically beneficial for their selves? 
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It is not only surveys in the U.S.A that promote the use of medical cannabis; surveys 
within Australia have presented a 69% support rate for the outright implementation 
of medical cannabis. Furthermore, 74% of the surveyed individuals were more 
favourable of a medical cannabis trial prior to a possible implementation (Wodak 
and Mather 2014, par.5). Similar figures are again supplied by the 2010 National 
Drug Strategy Household Survey Report by the Australian Institute of Health and 
Welfare; the Survey presented a 70% support rate for the implementation of 
medical cannabis and a further 75.5% endorsement rate of a trial (McGowan 2014, 
70). Research by Lenton and Ovenden has presented further Australian social 
acceptance of cannabis, they put forward that 64% of Australians support the use of 
medical cannabis (Lenton and Ovenden 1996, 790). Yet again, Australian support for 
medical cannabis can be seen in the form of the Help End Marijuana Prohibition 
(HEMP) party, the party placed 8th out of a possible 77 registered parties in the 2014 
Western Australian Senate election (Green 2014, par.16). 
Influential institutions in Australia such as the Cancer Council have recently 
expressed their support for the implementation of medicinal cannabis in Australia 
(Godfrey 2014, Growing support for medical cannabis, par.16). The Cancer council 
NSW has reportedly ‘recognised the medical capabilities of cannabis and has 
suggested decriminalisation of cannabis to approved patients’ (Cancer Council NSW 
2012, 1). Along with the NSW Cancer Council, the NSW Nurses and Midwives 
Association (NSWMNA) which has over 59 thousand employees (Godfrey 2014, Key 
nursing union backs medicinal cannabis, par.1) has also “formally endorsed” 
(Holmes and Kiejda 2014, 1) that Australia decriminalise cannabis for terminally ill 
patients. The NSWMNA has suggested that the government “support the use of 15g 
of dry cannabis on patients who have AIDS and other terminal illnesses” (Coultan 
2013, par.1). 
The Australian Medical Association has recently acknowledged the “therapeutic 
potential” (Sky News 2014, par.10) of cannabis. The Association has “called for 
clinical trials on the use of cannabis in order to establish its potential” (Cook and 
Smith 2014, par.13). The World Health Organization (WHO) is another organisation 
that supports the decriminalisation of medical cannabis, the WHO has 
‘acknowledged the therapeutic capabilities of cannabis in regard to its efficiency in 
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reducing nausea and vomiting’ (Cancer Council NSW 2012, 5). Material has 
presented that there are influential medical associations in Australia and abroad 
that encourage the legalisation of medical cannabis. This promotion of medical 
cannabis from influential organisations and associations within Australia and 
abroad, suggest that Australia would benefit from again researching the efficiency 
of medical cannabis.  
An influential actor for the promotion of medical cannabis in Australia is twenty-
four year old Daniel Haslam. Daniel has terminal bowl cancer and uses cannabis to 
reduce his nausea, poor appetite and constant vomiting (McGowan 2014, 70). 
Nationally, Daniel and his mother have collected over 200,000 signatures 
advocating the decriminalisation of medical cannabis for the terminally ill 
(McGowan 2014, 70). Daniel has featured in television programs, newspapers and 
online articles advocating medical cannabis. It is stories like Daniel’s that are putting 
pressure on the Australian government to reconsider their stance on medical 
cannabis. Surveys on over 3,400 Australia citizens present that the 51-65 year old 
age bracket is the section of the population that are most inclined to embrace the 
legalisation of medical cannabis (Cook and Smith 2014, par.2). Presented by the 
statistics, mature adults are amongst the individuals promoting the use of medical 
cannabis in Australia. It seems unethical to be denying informed individuals the 
right to be using medical cannabis, if the substance does hold medicinal value.  
3.3 Social advantages correlated with the legalisation of medical cannabis 
Certain individuals may be critical that the implementation of medical cannabis 
could have violent or dangerous social side effects. However it has been 
documented the environment, neighbourhood and social circumstances are the 
main catalyst to violence in areas where medical cannabis is available. This idea is 
presented in studies on areas in the U.S.A with ‘cannabis dispensaries’, cannabis 
dispensaries are businesses where medical cannabis is sold (Williams and Freisthler 
2011, 2). Sources of violence in areas where cannabis dispensaries are operational 
are presented to often suffer from similar catalysts of violence as areas without 
medical cannabis.  
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Catalysts of violence in these areas range from: ‘percentage of one person 
households, unemployment rates’ (Kepple and Freisthler 2012, 527) and “scale of 
income differences between rich and poor” (Wilkinson 2004, 1). Articles have even 
suggested that in Colorado where cannabis has recently been legalised, the overall 
crime rate has decreased by approximately 10.6% (Sarich, Colorado Sells $19 Million 
in Weed in March: $1.9 Million Goes to Schools and Crime Down 10% 2014, par.5).  
Further articles state that Denver, a town in Colorado has seen an estimated 14.6% 
drop in property crime and a further 2.4% drop in violent crimes since the medical 
dispensaries opened (Sarich, Colorado Crime Rates Down 14.6% Since Legalizing 
Marijuana 2014, par.2). An overall drop in crime of 10.6% has been presented in 
Denver since medical cannabis was legalised (Diente 2014, par.8).  
Further material presents that the legalisation of ‘medical cannabis dispensaries can 
be correlated with a reduction in homicide, assault and other crimes’ (Morris, et al. 
2014, 1). The research suggests that the increased security measures within 
cannabis dispensaries such as: internal and external security cameras, doormen and 
requirement for all customers to carry valid identification can eventually increase 
local security. It has been suggested that security upgrades within cannabis 
dispensaries can inevitably lead to an overall reduction in homicide, assault and 
burglary crime rates within the vicinity of a medical cannabis dispensary (Morris, et 
al. 2014, 2). Further material presents cannabis to possibly reduce domestic 
violence within married couples. During a nine yearlong study that used numerous 
married couples as test subjects, the study presented that cannabis use was related 
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Figure 11  
(Morris, et al. 2014, 5) 
 
Figure 12 
(Sarich, Colorado Sells $19 Million in Weed in March: $1.9 Million Goes to Schools 
and Crime Down 10% 2014) 
 
Figures 11 (R.Morris, et al. 2014, 5) illustrates a drop in violent and property crime 
within one year of medical cannabis implementation. 
Figures’ 12 (Sarich, Colorado Sells $19 Million in Weed in March: $1.9 Million Goes to Schools 
and Crime Down 10% 2014) illustrates the correlation between medical cannabis 
implementation and a decreased homicide and aggravated assault rate in Denver, U.S.A. 
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Although cannabis is illegal in Australia, it has already been presented in this thesis 
that Australians are some of the largest consumers of cannabis in the world (Baxter, 
Baker and Reece 2013, 1). However many Australians still fear using cannabis due to 
its current legal status (Topp 2006, 13), this point is supported when it is stated that 
many Australian cancer patients fear breaking the law to obtain cannabis (ABC 
News 2014, The Cancer Council calls for mature debate on cannabis, par.8). 76% of 
surveyed non-cannabis users in Australia suggested that legal repercussions and 
fear of arrest currently deter them from using medical cannabis (Swift, Gates and 
Dillon 2005, 7). Research has presented that 62% of surveyed Australians would use 
medical cannabis if it were legal (Janichek and Reiman 2012, 1). Accessing illegal 
cannabis can put a patient in contact with criminal networks (Australian Medical 
Association 2014, 4); therefore many ill Australians rightfully choose to go without 
the substance.  
             
(Diehm and Hall 2013) 
 
 
Despite its illegal status, it has been suggested that a large number of Australians 
would still be inclined to use cannabis for medical reasons if it were not for the high 
prices of the substance (Topp 2006, 13). 51% of Australians stated that at an 
average of $25 per gram, cannabis is too expensive to use as a frequent medicine 
(Swift, Gates and Dillon 2005, 7).  If cannabis were to be legalised, it has been 
suggested that the price would significantly drop from $25 per gram. As presented 
Figure 13 (Diehm and 
Hall 2013) highlights 
how implementing 
medical cannabis may 
reduce its high prices. 
Figure 13 
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in Figure 13 (Diehm and Hall 2013), it has been suggested that cannabis price could 
fall from $375 dollars per ounce to $38. This drop in price would ultimately mean 
that more individuals could afford to use cannabis for medical reasons. 
 
Due to cannabis being illegal in Australia, many individuals can and have been 
arrested for possessing the substance. In a survey of 147 Australians that illegally 
purchase cannabis to use for medical reasons, it was presented that 27% of the 147 
individuals surveyed had been either been “arrested, cautioned or convicted in 
relation to their cannabis use” (Swift, Gates and Dillon 2005, 7).  
 
An example of Australian’s being arrested for self-prescribing themselves medical 
cannabis can be seen in the case of Cassie Batten and Rhett Wallace who were 
taken into custody after being found with small amounts of cannabis oil, the couple 
had used the oil to treat their own epilepsy (Harrison, Spooner and Donnelly 2014, 
par.1-2). A similar case of an Australian being arrested for using cannabis for 
medically is evident in the case of a 59-year-old South Australian man who was 
suffering leukaemia; he was imprisoned for two years after being convicted of 
growing cannabis (Wodak and Mather 2014, par.3).  
 
This high level of cannabis related conviction is troubling for many reasons, for 
example the Australian Medical Association suggests that criminal convictions can 
often “negatively impact” on an individual’s life, long after their conviction.  For 
example, “a criminal conviction can negatively impact on a person’s employment 
prospects and their accommodation and travel opportunities” (Australian Medical 
Association 2014, 4).  
Suggestibly there is an ethical debate regarding individuals being arrested for using 
cannabis for medical purpose. If these imprisoned Australians were citizens of a 
medical cannabis country such as the Czech Republic or Netherlands, they would be 
free to use cannabis medically and without imprisonment.  
(Diehm and Hall 2013) 
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When 400 Western Australians were surveyed in regard to their opinions on 
cannabis’ legality, it was presented that 2/3rds of the respondents were concerned 
that cannabis being illegal could eventually overburden the court system with 
unneeded cannabis cases (Lenton and Ovenden 1996, 783).  
Within Evans’ literature, a similar opinion is presented when he puts forward that 
decimalising cannabis for ill patients could ultimately ‘free up the prison system’ 
(Evans 2013, 5). It has been presented that decriminalising cannabis could save the 
government of the U.S.A an estimated 13.7 Billion in prosecutorial, judicial, and 
correctional and police spending (Evans 2013, 2). If Australia were to follow the 
path of the U.S.A in respect to medical cannabis, Australia could benefit financially 
like the U.S.A has. 
The Dutch coffeshoppe design is a unique social experiment that has been 
successful in the Netherlands, the Dutch government made it legal to purchase and 
consume cannabis in specific “coffeshoppes”. The Dutch government suggested this 
‘cannabis friendly zone’ would provide an environment for users of cannabis to use 
and obtain their cannabis in safety. By providing an environment solely for the 
purchase of cannabis, cannabis users were able to avoid meeting up with criminal 
groups or drug dealers to obtain their cannabis. Since there was no longer a 
required contact with drug dealers, the coffeshoppes were seen to reduce the 
consumption ‘harder drugs’. It was presented that cannabis users in the 
Netherlands were no longer as freely exposed to other ‘harder drugs’, because 
these coffeshoppes only exposed them to cannabis use (MacCoun and Reuter 2011, 
69). In theory, a similar policy to the Dutch coffeshoppe design can be a possible 
way of administering medical patients’ cannabis in Australia. Perhaps it would be 
possible to construct a medical coffeshoppe that only serves individuals with a valid 
medical script or card. However if this medical coffeshoppe was to be pursued any 
further, there would have to be supporting research by the Australian government 
to suggest medical cannabis is beneficial to these patients.  
If medical cannabis were to be pursued in Australia, European trends suggest that 
the overall number of illegal cannabis crops will decrease (Decorte 2010, 271). This 
reduction in illegal cannabis crops can reduce the amount of drug dealers and 
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certain illegal activity within the country. This idea is reinforced by Klofas when he 
puts forward that in specific cases in the U.S.A, the implementation of medical 
cannabis has been correlated with a reduction in street, gang and drug crime. Klofas 
concludes his support of medical cannabis when stating that ‘cannabis purchased 
within a medical facility is safer than individuals purchasing cannabis from a drug 
dealer (Klofas and Letteney 2012, 4).  
3.4 Economic debates for legalising medical cannabis 
A final debate that is presented for the implementation of medical cannabis is the 
illusive profit local governments can gain from the industry, Klofas calls it a “very 
influential source of income and wealth” (Klofas and Letteney 2012, 4). In the U.S.A, 
the Colorado medical cannabis industry generated approximately $1.5 million USD 
solely in the month of January 2014 (McKay 2014, par.1).   
Colorado generated $5.3million USD after three months (McKay 2014, par.1), it has 
been calculated that Colorado can expect to generate approximately $18million 
USD from medical cannabis by the end of 2014.  (Phillips 2014, Colorado Pulls In 
Millions In Marijuana Tax Revenue, par.1).  In 2011 cannabis totalled as an equitable 
11 Billion dollar industry in the U.S.A (Klofas and Letteney 2012, 4), this equitable 
cannabis industry could financially benefit Australia if they were to industrialise 
medical cannabis like in case of the U.S.A. 
Medical cannabis might not only provide the chance for the Australian government 
to gain a new lucrative industry, it could also generate careers for many individuals 
in this new industry. In the cases of medical cannabis being supplied in Canada and 
certain states of the U.S.A, “there are a wide range of direct and indirect 
employment gains being measured” (Washer and Langman 2014, par.24).  New 
careers can develop upon medical cannabis becoming implemented such as 
cannabis trimmers, farmers, journalists and business owners (McKay 2014, par.3). 
Within the U.S.A, over 2,000 medical cannabis centers employ several thousand 
employees (Knight and Smith 2014, par.6). In reference to Washington, 10,000 new 
jobs have arisen due to the legalisation of both recreational and medical cannabis 
(Sarich 2014, Colorados marijuana legalization creates 10000 new jobs, par.1). Over 
2,000 new jobs have been produced within the last few months alone and 
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Washington has been witnessing one of the lowest unemployment rates in the 
U.S.A (Sarich 2014, Colorados marijuana legalization creates 10000 new jobs, par.1). 
It has been presented in numerous materials that Australia has a perfect climate to 
grow natural outdoor cannabis. This is supported when Jiggens presents that “In 
1964, a massive infestation of wild cannabis was found growing along a stretch of 
the Hunter River between Singleton and Maitland in New South Wales” (Jiggens 
2004, 3). This ability to grow outdoor cannabis is economically advantageous, since 
certain countries that already have medical cannabis for example Canada, spend 
“huge energy costs” on sustaining their indoor medical cannabis grows (due to 
inadequate natural climate for growth) (Washer and Langman 2014, par.21). Due to 
their frequently cold European weather, it would be fair to assume the Netherlands 
and Czech Republic would also suffer from the same growing predicament as 
Canada.  
With a climate and farming industry that is prosperous for growing crops (National 
Farmers Federation 2012, 5), the medical cultivation of cannabis can be seen as 
smart economics for Australia. Tasmania already has a successful pharmaceutical 
poppy industry that could make an ideal and secure facility to grow medical 
cannabis. The Tasmanian farmers lobby have been quoted to have “welcomed the 
idea of growing medical cannabis in the state” (ABC News 2014, State Health 
Minister to discuss medical cannabis trials at the University of Tasmania, par.19). 
Chapter 3 Conclusion 
In summary this chapter has discussed the current legal status of cannabis in 
Australia, followed by the political, social and legal acceptance of medical cannabis 
in the country. This chapter has presented medical cannabis to be a substance that 
can have certain political, social and economic value. Medical cannabis’ 
implementation can lead to a reduction in crime, increase in economic revenue and 
increase in job opportunities. Medical cannabis can also reduce government, police 
and judicial spending. Therefore it has been presented within this chapter that 
medical cannabis can often be a valuable industry; if implemented correctly a 
medical cannabis industry could be financially beneficial for Australia. 
Michael Leo Hawkins, B.A. 31218899SWM617 Research Thesis 2014 Supervisor: Professor S.Makinda 
45 | P a g e  
 
Chapter 4: The Conclusion 
Chapter 4 Introduction 
This final chapter will summarise the overall hypothesis of this thesis by concluding 
that there is abundant evidence to suggest that medical cannabis is an extremely 
valuable resource both socially and medically. This thesis suggests that due to a lack 
in solid research on medical cannabis, Australia is lagging behind the numerous 
developed countries have already implemented cannabis for medical use. 
Discussion 
As presented by certain developed states adopting the use of medical cannabis in 
recent years, medical cannabis has become an increasingly accepted medical tool 
internationally. Further research on medical cannabis in Australia could finally 
resolve the issue of cannabis’ legitimacy in medical use. Such a trial could possibly 
present the Australian government enough information to legalise medical 
cannabis.  
This thesis has presented that medical cannabis use can be an effective way of 
treating numerous medical conditions. Cannabis has been presented throughout 
this thesis to be an efficient analgesic (painkiller) for humans, for this reason it has 
been heavily documented that cannabis can be used as an effective substitute for 
certain pharmaceutical medications as well as alcohol, tobacco and other illegal 
drug use. This thesis has presented many alternative methods to cannabis use that 
do not involve the heavily tabooed act of smoking, methods such cannabis oil, 
spray, edible foods, tablets and vaporisers are all available.  
Unlike many conventional medications, cannabis is suggested to be a fast acting 
drug; results are often visible within 2-3 days. Also unlike many pharmaceutical 
drugs, cannabis is unique in the fact that humans are suggested to be unable to 
overdose from its use,  in fact the main side effect to cannabis use if often 
‘dizziness’. Another method that suggests medical cannabis to be safe is the fact 
that cannabis can now be personally tailored to a patients needed requirement. 
This ensures that the patient is neither receiving more or less that their required 
dose of cannabinoids.  
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Cannabis has been tested and supplied to many patients internationally for the 
treatment of numerous illnesses. Internationally, cannabis has already been 
prescribed to sufferers of: cancer, HIV/AIDS, nausea, ‘MS’, epilepsy, strokes, 
arthritis, diabetes, Hepatitis-c, ‘PTSD’, psychosis, depression, schizophrenia, spasms, 
neurodegeneration, heart attack, glaucoma, ‘IBS’, sleeping problems and lack of 
appetite; not to name them all.  
Besides medical advantages, the implementation of medical cannabis within 
Australia can also provide numerous political and socio-economic advantages. 
Currently individuals who illegally source themselves cannabis, often run the risk of 
being jailed or fined if caught by police with cannabis. If medical cannabis were to 
be implemented in Australia, patients will no longer run the gauntlet of being 
imprisoned or having to associate with drug dealers to obtain cannabis.  
Legalised medical cannabis will provide a safe grade of cannabis, to legitimate 
patients from a safe and legal environment. Medical cannabis legalisation has been 
presented within this thesis to correspond with a decreased crime rate and reduced 
amount of illegal cannabis grows in Europe. Significant research has also presented 
medical cannabis to be a significant catalyst towards a reduced rate of violence and 
assault. Further social acceptance of cannabis is evident within Australia, as it is the 
largest consumed drug in the country.  Australian citizens are also cited as being 
one of the largest consumers of cannabis in the world along with geographical 
neighbours New Zealand. This thesis has ultimately suggested that the 
implementation of medical cannabis can assist with numerous social conundrums in 
Australia. 
Legalising medical cannabis could also be an economically advantageous move for 
the Australian government. As presented by certain cases in the U.S.A, medical 
cannabis is a multi-million dollar industry which could open many employment 
opportunities in the country. Presented in certain examples from the U.S.A, by 
legalising medical cannabis the Australian government could save millions of dollars 
in prosecutorial, judicial, correctional and police spending.  As evident by wild 
cannabis crops found in Australia, the country has a suitable climate for outdoor 
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cannabis cultivation; Australia also has a pre-existing, highly functional farming 
industry that could successfully cultivate medical cannabis. 
Possible methods to implement the legal sales of medical cannabis in Australia 
could come in the forms of decriminalised cannabis use for the legitimately ill, as 
mentioned in the bills presented by Australian politicians that include Anderson, 
O’Grady and Carr. Other methods such as a medical coffeshoppe that follows the 
design of the Dutch coffeshoppe are also possible. However if any of these 
processes are to occur, Australia needs to hold mature political debate as well as 
medical research on the topic of medical cannabis. In order to successfully 
implement medical cannabis the Australian government must change its current 
drug policy on cannabis. This thesis has presented material which suggests that it is 
advisable for Australia to consider changing its current legislation on cannabis by 
first researching the use of medical cannabis.  
Chapter 4 Conclusion 
The hypothesis of this thesis is that there is abundant evidence to suggest that 
medical cannabis is an extremely valuable resource both socially and medically. 
Overall this thesis has provided evidence to suggest that if implemented correctly, 
medical cannabis can be a valuable resource both socially and medically. In 
conclusion this thesis has debated that by following the example of countries that 
have already legalised medical cannabis; the implementation of medical cannabis’ 
in Australia is not only medically beneficial but also socially, politically and 
economically beneficial. Therefore this thesis suggests that Australia first research 
the efficiency of medical cannabis, in order to finally resolve the debates 
surrounding the implementation of legalised medical cannabis in Australia. 
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